Bayer Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 2/6

Bayer hat ein Gesamteigenkapital von €35.8B und eine Gesamtverschuldung von €45.3B, wodurch sich der Verschuldungsgrad auf 126.5% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen €119.9B bzw. €84.0B. Bayer Das EBIT des Unternehmens beträgt €7.2B, so dass der Zinsdeckungsgrad 8.6 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von €10.0B.

Wichtige Informationen

126.5%

Verhältnis von Schulden zu Eigenkapital

€45.33b

Verschuldung

Zinsdeckungsgrad	8.6x
Bargeld	€10.02b
Eigenkapital	€35.85b
Gesamtverbindlichkeiten	€84.01b
Gesamtvermögen	€119.86b

Jüngste Berichte zur Finanzlage

Keine Aktualisierungen

Recent updates

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: BAYDie kurzfristigen Aktiva des Unternehmens (€40.1B) übersteigen seine kurzfristigen Passiva (€31.6B).

Langfristige Verbindlichkeiten: BAYDie kurzfristigen Vermögenswerte des Unternehmens (€40.1B) decken seine langfristigen Verbindlichkeiten (€52.5B) nicht.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: BAYDie Nettoverschuldung im Verhältnis zum Eigenkapital (98.5%) wird als hoch angesehen.

Schulden abbauen: BAYDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 93.5% auf 126.5% gestiegen.

Schuldendeckung: BAYDie Schulden des Unternehmens sind nicht ausreichend durch den operativen Cashflow (18.6%) gedeckt.

Zinsdeckung: BAYDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (8.6x Coverage) gut gedeckt.

Bayer Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Recent updates

Bayer and Liveo Research Launches Blister Packaging with Improved Environmental Footprint

Bayer Submits Application for Third Indication of Darolutamide in the EU

U.S. Food and Drug Administration Accepts New Drug Application for Bayer's Elinzanetant

Bayer Ag and BlueRock Therapeutics LP Announces Positive 24-Month Data from exPDite

Bayer Submits Application to U.S. FDA for Third Indication of darolutamide

New minor risk - Share price stability

Bayer to Unveil New Data from its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Bayer Announces Late-Breaking KERENDIA® (finerenone) Investigational Data Presented

Bayer to Present Phase III Kerendia (Finerenone) Data

New minor risk - Share price stability

Second quarter 2024 earnings released: €0.03 loss per share (vs €1.92 loss in 2Q 2023)

Bayer Announces Primary Endpoint Achieved in Phase III FINEARTS-HF Cardiovascular Outcomes Study Investigating KERENDIA in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Bayer Submits New Drug Application to U.S. FDA for Elinzanetant for the Treatment of Moderate to Severe Vasomotor Symptoms Associated With Menopause

Bayer Presents Latest Data from Oncology Portfolio at 2024 ASCO Annual Meeting

Bayer Starts Phase I Study with Novel Targeted Radionuclide Therapy 225Ac-Psma-Trillium in Advanced Metastatic Prostate Cancer

First quarter 2024 earnings released: EPS: €2.04 (vs €2.22 in 1Q 2023)

Bayer to Unveil Late-Breaking Data from Phase Iii Oasis 1 and 2 for Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Bayer AG and Asklepios BioPharmaceutical, Inc Presents Results from the 18-Month Phase Ib Clinical Trial for AB-1005

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Bayer Announces Positive Topline Results from Phase III Long-Term Study Oasis 3 Support Submits for Marketing Authorization for Bayer's Elinzanetant

Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025

Full year 2023 earnings released: €2.99 loss per share (vs €4.22 profit in FY 2022)

Bayer Announces Start of Phase II Clinical Trial with BAY3018250

Bayer Aktiengesellschaft, Annual General Meeting, Apr 26, 2024

Now 23% undervalued after recent price drop

Bayer Aktiengesellschaft to Report Q4, 2023 Results on Mar 05, 2024

Bayer Announces Key Leadership Changes for its Crop Science Division

Bayer Starts Phase II Study Nirvana to Evaluate Elinzanetant in Women with Sleep Disruptments Associated with Menopause

Williams Hart & Boundas Wins Against Bayer

Now 20% undervalued after recent price drop

Now 23% undervalued after recent price drop

Bayer Announces OCEANIC-AF Study Starts Early Due to Lack of Efficacy

Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination

Bayer Provides Update on Aliqopa (Copanlisib)

Third quarter 2023 earnings released: €4.66 loss per share (vs €0.56 profit in 3Q 2022)

Bayer Announces Pharmacodynamic Data on Kerendia

Bayer Aktiengesellschaft to Report Q3, 2023 Results on Nov 08, 2023

Bayer to Present Latest Real-World Evidence of Menopausal Symptoms and Their Treatment

Bayer Aktiengesellschaft (XTRA:BAYN) signed an agreement to acquire strawberry pipeline and commercial portfolio from NIAB.

Bayer AG and BlueRock Therapeutics LP Announces Details of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (BRT-DA01), A Stem Cell Derived Investigational Therapy for Treating Parkinson's Disease

Bayer AG and Bluerock Therapeutics LP Announces Results of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (Brt-Da01)

Bayer AG Announces Management Changes

New minor risk - Profit margin trend

Second quarter 2023 earnings released: €1.92 loss per share (vs €0.30 loss in 2Q 2022)

Bayer Aktiengesellschaft Provides Earnings Guidance for Full-Year 2023

Industrias Químicas del Valles S.A. reached an agreement to acquire Bayer's phytosanitary products factory in Valencia from Bayer Aktiengesellschaft (XTRA:BAYN).

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen